Hematology | Clinical

April 26, 2021

Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.

April 26, 2021

An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.

April 26, 2021

Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.

April 26, 2021

An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.

April 26, 2021

Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.

April 26, 2021

An expert hematologist-oncologist reviews the standard of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM and explores the role of quadruplet induction regimens.

April 26, 2021

Clifton C. Mo, MD, presents the case of a 79-year-old woman with R-ISS stage I multiple myeloma and shares his initial impressions.

April 26, 2021

Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.

April 22, 2021

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

April 22, 2021

Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.